You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Dynamic Frequency Passive Millemeter-Wave Radiometer Based on Optical Up-Conversion

    SBC: PHASE SENSITIVE INNOVATIONS INC            Topic: 94

    Passive microwave sensors aboard satellites provide valuable information regarding weather conditions by measuring atmospheric attenuation over a broad range of frequencies from 0-200 GHz. Additional ground-based sensors are desirable to provide complementary upward looking measurements that can be used to refine existing attenuation models. Operating over such a large bandwidth, however, places ...

    SBIR Phase II 2014 Department of CommerceNational Oceanic and Atmospheric Administration
  2. IGF::OT::IGF

    SBC: DIAGNOSTIC PHOTONICS, INC.            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Therapeutic for Invasive Candidiasis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Systemic fungal infections are increasingly common, especially in immune compromised patients. While new antifungal drugs have been developed, there is still a high mortality associated with these infections, especiallythose due to Candida albicans, other non-albicans species (NAS). This is due to the limited spectrum of the drugs, significant side effects, as ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Utilization of a Novel Aerosol-Generating Technology to Deliver Luc

    SBC: DISCOVERY LABORATORIES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Respiratory distress syndrome (RDS) is an acute, severe pulmonary disorder that is the leading cause of morbidity and mortality in preterm infants. It is a major healthcare concern - costs associated with treatment of RDS and its complications exceed 2.4 billion annually in the US. Currently, animal-derived surfactants instilled intratracheally via an endotrac ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Infection resistant surface for ventricular assist device (VAD) transcutaneous dr

    SBC: ENSION Inc            Topic: NHLBI

    DESCRIPTION (provided by applicant): Infection is a common and frequently very serious complication associated with medical implants. Man-made materials, including those used to fabricate ventricular assist devices (VADs), compromise the body's ability tofight infection in tw ways. First, by breaching skin with transcutaneous cannulae and drivelines, and second, by eliciting a foreign body re ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. KL4 Surfactant to Mitigate Radiation-Induced Lung Injury

    SBC: DISCOVERY LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Exposure to ionizing radiation from a nuclear reactor accident or deliberate terrorist actions including the detonation of andquot dirty bombsandquot is a significant public health concern The lung is particularly susceptible to ionizing radiation injury from external sources or inhalation of radioactive particles from radioactive fall out Radiation pneumono ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Therapeutic for Invasive Candidiasis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION provided by applicant Systemic fungal infections are increasingly common especially in immune compromised patients While new antifungal drugs have been developed there is still a high mortality associated with these infections especially those due to Candida albicans other non albicans species NAS This is due to the limited spectrum of the drugs significant side effects as ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Small Molecule Inhibitor for EBV Latent Infection

    SBC: VIRONIKA LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this research program is to develop a novel small molecule inhibitor of latent Epstein Barr Virus EBV infection EBV is a ubiquitous gamma herpesvirus that has been classified by the World Health Organization as a human carcinogen Vironika with its consortium partners the Wistar Institute and Fox Chase Chemical Diversity Center Inc will deve ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Clinically Viable Pattern Recognition Embedded System

    SBC: Coapt LLC            Topic: NICHD

    DESCRIPTION provided by applicant Pattern recognition PR myoelectric control systems can dramatically improve an amputee patientandapos s control of a powered prosthesis but they have not been made commercially available Coapt LLC is a start up stage company that has initiated a controlled commercial release of PR myoelectric control for the benefit of upper limb amputees The controlle ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Modulators of LDL Metabolism

    SBC: SHIFA BIOMEDICAL CORPORATION            Topic: NHLBI

    DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achiev ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government